Erratum: Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey (International Journal Antimicrobial Agents (2004) 23 (510-512) DOI: 10.1016/j.ijantimicag.2003.09.029);Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey

International Journal of Antimicrobial Agents

Volumn 23, Issue 5, 2004, Pages 510-512

  Baysallar, Mehmet ^a   Kilic, Abdullah ^a   Aydogan, Hakan ^a   Cilli, Feriha ^b   Doganci, Levent ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Linezolid; Methicillin resistant Staphylococcus aureus; Quinupristin dalfopristin; Vancomycin resistant enterococci

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; LINEZOLID; METICILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONTROLLED STUDY; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TURKEY (REPUBLIC);

EID: 2342576860     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2004.10.006     Document Type: Erratum

References (9)

1. Luh K.T., Hsueh P.R., Teng L.J., Pan H.J., Chen Y.C., Lu J.J., et al. Quinupristin-dalfopristin resistance among Gram-positive bacteria in Taiwan. Antimicrob. Agents Chemother. 44:2000;3374-3380
2. Karadenizli A. Hastanelerde metisilin dirençli Staphylococcus aureus (MRSA) kontrol politikalari ve MRSA. Hastane Infeksiyonlari Dergisi. 6:2002;12-18
3. Bassetti M., Di Biagio A., Cenderello G., Del Bono V., Palermo A., Cruciani M., et al. Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA). J. Infect. 43:2001;148-149
4. National Committee for Clinical Laboratory Standards, 2000. Performance standards for antimicrobial susceptibility testing: eighth informational supplement. NCCLS Document M100-S8. NCCLS, Villanova, PA.
5. Jones R.N., Low D.E., Pfaller M.A. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant Gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn. Microbiol. Infect. Dis. 33:1999;101-112. (review)
6. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:1997;135-136
7. Noskin G.A., Siddiqui F., Stosor V., Hacek D., Peterson L.R. In vitro activities of linezolid against important Gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 43:1999;2059-2062
8. Jones RN, Pfaller MA, Erwin ME, Beach ML. Antimicrobial activity of linezolid tested against 7, 599 recent clinical isolates from over 50 medical center laboratories. In: Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract 1263, 26-29 September 1999, San Francisco, CA.
9. Jones R.N., Ballow C.H., Biedenbach D.J., Deinhart J.A., Schentag J.J. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid®) tested against over 28, 000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn. Microbiol. Infect. Dis. 31:1998;437-451